SCHEMBL432601

SCHEMBL432601

O=[N+]([O-])c1cc(F)c(Cl)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.50
ATM Q13315 1/20 0.50
ALDH1A1 P00352 7/20 0.48
HIF1A Q16665 2/20 0.48
VCAM1 P19320 3/20 0.46
TSHR P16473 4/20 0.45
MAPK1 P28482 1/20 0.45
ESPL1 Q14674 1/20 0.44
CYP3A4 P08684 2/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
TXNRD1 Q16881 1/20 0.42
TXNRD3 Q86VQ6 1/20 0.42
TXNRD2 Q9NNW7 1/20 0.42
MAPT P10636 2/20 0.42
GPR35 Q9HC97 2/20 0.41
SLC6A4 P31645 1/20 0.40
MITF O75030 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29739925 1.00 TDP1 (0.50) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL30953155 0.91 TDP1 (0.50) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL138641 0.91 TDP1 (0.50) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL29580289 0.89 TDP1 (0.52) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL14578462 0.89 TDP1 (0.52) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL123793 0.89 TDP1 (0.52) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL3543539 0.87 TSHR (0.50) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL8967138 0.87 TDP1 (0.50) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL30110338 0.87 TSHR (0.50) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL30434858 0.87 TDP1 (0.50) TDP1ATMALDH1A1HIF1AVCAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090330-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 WO disclosed
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2026-04-09 US disclosed
EP-4696688-A1 BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2026-02-18 EP disclosed
US-12466815-B2 Carboxamide compounds and uses thereof INCYTE CORPORATION (US) 2025-11-11 US disclosed
US-12458642-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-11-04 US disclosed
US-20250333429-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS INC (US) 2025-10-30 US disclosed
US-12384808-B2 Modulators of TNF-α activity FORWARD THERAPEUTICS, INC. (US) 2025-08-12 US disclosed
EP-3562306-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2025-02-26 EP disclosed
US-20240376059-A1 Compounds for the Treatment of Alzheimer's Disease THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2024-11-14 US disclosed
WO-2024220891-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2024-10-24 WO disclosed
US-6251903-B1 Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist COCENSYS, INC. 2001-06-26 US disclosed
US-6147075-A ANALGESICS; PSYCHOLOGICAL DISORDERS COCENSYS, INC. (US) 2000-11-14 US disclosed
EP-0732942-A4 ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS COCENSYS INC (US) 2000-03-22 EP disclosed
US-5977107-A Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists COCENSYS, INC. (US) 1999-11-02 US disclosed
US-5631373-A NERVOUS SYSTEM DISORDERS STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-05-20 US disclosed
EP-0732942-A1 ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS ACEA PHARMACEUTICALS, INC. (US) 1996-09-25 EP disclosed
WO-1995012417-A1 ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS ACEA PHARMACEUTICALS, INC. (US) 1995-05-11 WO disclosed
US-5283248-A Bactericides, enzyme inhibitor of DNA-gyrase in bacteria HOFFMANN-LA ROCHE INC. (US) 1994-02-01 US disclosed
EP-0433648-A1 Substituted pyrimidobenzimidazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1991-06-26 EP disclosed
EP-0430847-A1 Procedure for the preparation of N-cyclopropyl-4-fluoroanilines CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) 1991-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458642-B2 Metalloenzyme inhibitor compounds CYP11B2, CYP11B1, HSD11B2 TDP1 2721/4885ATM 4026/4885ALDH1A1 232/4885
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CPN1, TPP1, DPP4 TDP1 692/4885ATM 4632/4885ALDH1A1 189/4885
US-20240376059-A1 Compounds for the Treatment of Alzheimer's Disease IAPP, GPR119, APP TDP1 1690/4885ATM 1025/4885ALDH1A1 4515/4885
US-12384808-B2 Modulators of TNF-α activity TNF, NFKBIA, TNFRSF1A TDP1 1576/4885ATM 3969/4885ALDH1A1 2291/4885
US-20250333429-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, NFKBIA, TNFRSF1A TDP1 1311/4885ATM 4047/4885ALDH1A1 2563/4885
US-12466815-B2 Carboxamide compounds and uses thereof PCK1, PHKG2, PHKG1 TDP1 1427/4885ATM 2308/4885ALDH1A1 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.